New treatment option for decreasing blood cholesterol level - Clinical importance of dual inhibition of cholesterol-absorption and synthesis;A vérkoleszterinszint-csökkentésének új lehetosége - A koleszterinfelszívódás és szintézis együttes gátlásának klinikai jelentosége

Orvosi Hetilap

Volumn 145, Issue 15, 2004, Pages 805-811

  Paragh, György ^a,c   Márk, Lászlo ^b   Czine, Zsigmond ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Bekes Megyei Kepviselo testulet Pandy Kalman Korhaz   (Hungary)

^c Nagyerdei KRT 98   (Hungary)

Author keywords

Cholesterol; Combination therapy; Ezetimibe; Statin

Indexed keywords

CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; HYPERCHOLESTEROLEMIA; REVIEW; BIOSYNTHESIS; BLOOD; DRUG COMBINATION; DRUG EFFECT; DRUG TOLERANCE; HUMAN; INTESTINE ABSORPTION; LIVER; METABOLISM;

AZETIDINE DERIVATIVE; CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION; LIVER;

EID: 3242727065     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Barter, P. J., O'Brien, R. C.: Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. Atherosclerosis, 2000, 149, 199-205.
2. Bauer, K. S., Kosoglou, T., Statkevich, P., és mtsai: Ezetimibe does not affect the pharmacokinetics of pharmacodynamics of warfarin. Clin. Pharmacol. Ther., 2001, 69, P5 (abstract).
3. Bays, H., Drehobl, M., Rosenblatt, S. és mtsai: Low-density lipoprotein cholesterol reduction by SCH58235 (ezetimibe), a novel inhibitor of intestinal cholesterol absorption in 243 hypercholesterolemic subjects: Results of dose-response study. Atherosclerosis, 2000, 151, 133 (abstract).
4. Bays, H. E., Dujovne, C. A.: Lipid-altering drugs in development. Drugs Rd. 1999, 1, 463-469.
5. Beisiegel, U.: Lipoprotein metabolism. Eur. Heart. J., 1998, 19 (Suppl. A), A20-23.
6. Black, D. M., Bakker-Arkema, R. G., Nawrocki, J. W.: An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch. Intern. Med., 1998, 158, 577-584.
7. Clifton, P. M., Noakes, M., Nestel, P. I.: LDL particle size and LDL and HDL cholesterol changes with dietary fat and cholesterol in healthy subjects. J. Lipid. Res., 1998, 39, 1799-1804.
8. Cohn, J. S.: Postprandial lipemia: emerging evidence for atherogenicity of emnant lipoproteins. Can. J. Cardiol., 1998, 14 (Suppl. B), 18B-27B.
9. Davidson, M. H., Dillon, M. A., Gordon, B. és mtsai: Colesevelam hydrochloride (Cholestagel). A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med., 1999, 159, 1893-1900.
10. Davis, H. R., Compton, D. S., Hoos, L. és mtsai: Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte cholesterol uptake and absorption. Eur. Heart. J., 2000, 21 (Suppl), 636 (abstract).
11. Davis, H. R., Compton, D. S., Hoos, L. és mtsai: The cholesterol inhibitor ezetimibe inhibits the development of atherosclerosis in apo E knockout (-/-) mice fed low fat and western diets. Atherosclerosis, 2000, 151, 133 (abstract).
12. Davis, H. R., vanHeek, M., Watkins, R. W. és mtsai: The hypocholesterolemic activity of the potent cholesterol absorption inhibitor SCH58235 alone and in combination with HMG CoA reductase inhibitors. In: Program and abstracts of Drugs Affecting Lipid Metabolism, November 7-10, 1995, Houston, Texas (abstract).
13. Davis, H. R., Watkins, R. W., Compton, D. S. és mtsai: The cholesterol absorption inhibitor ezetimibe (SCH58235) and lovastatin synergistically lower plasma cholesterol and inhibit the development of atherosclerosis. J. Am. Coll. Cardiol., 2000, 35 (Suppl. A), 252 (abstract).
14. Dietschy, J. M.: Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Am. J. Clin. Nutr., 1997, 65 (Suppl.), 1581S-1589S.
15. Edington, J., Geekie, M., Carter, R. és mtsai: Effects of dietary cholesterol on plasma cholesterol concentration in subjects following reduced fat, high fibre diet. BMJ, 1987, 294, 333-336.
16. Edington, J. D., Geekie, M., Carter, R. és mtsai: Serum lipid response to dietary cholesterol in subjects fed a low- fat, high-fibre diet. Am. J. Clin. Nutr., 1989, 50, 58-62.
17. Ernst, N. D., Cleeman, J., Mullis, R. és mtsai: The National Cholesterol Education Program: implications for dietetic practitioners from the Adult Treatment Panel recommendations. J. Am. Diet. Assoc., 1988, 88, 1401-1408, 1411.
18. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001, 19, 2486-2497.
19. Ginsberg, H. N., Karmally, W., Siddiqui, M. és mtsai: Increases in dietary cholesterol are associated with modest increases in both LDL and HDL cholesterol in healthy young women. Arterioscl. Thromb., 1995, 15, 169-178.
20. Ginsberg, H. N., Karmally, W., Siddiqui, M. és mtsai: A dose-response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young men. Arterioscl. Thromb., 1994, 14, 576-586.
21. Hallikainen, M. A., Sarkkinen, E. S., Usitupa, M. I. J.: Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J. Nutr., 2000, 130, 767-776.
22. Kern, Jr. F.: Effects of dietary cholesterol on cholesterol and bile acid homeostasis in patients with cholesterol gallstones. J. Clin. Invest., 1994, 93, 1186-1194.
23. Keung, A. C. F., Kosoglou, T., Statkevich, P. és mtsai: Ezetimibe does not affect the pharmacokinetics of oral contraceptives. Clin. Pharmacol. Ther., 2001, 69, P55 (abstract).
24. Knopp, H.: A double-blind, randomized trial of the effects of two eggs per day in moderately hypercholesterolemic and combined hyperlipidemia subjects consuming the NCEP Step I diet. American Heart Association, Anaheim, CA. 1995.
25. Knopp, R. H., Bays, H., Manion, C. V. és mtsai: Effect of ezetimibe on serum concentrations of lipid-soluble vitamins. Atherosclerosis 2001, 2 (Suppl.), 90 (abstract).
26. Knopp, R. H.: Drug treatment of lipid disorders. N. Engl. J. Med., 1999, 341, 498-511.
27. Kosoglou, T., Guillaume, M., Sun, S. és mtsai: Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe. Atherosclerosis 2001, 2 (Suppl), 38 (abstract).
28. Kosoglou, T., Meyer, I., Musiol. B. és mtsai: Pharmacodynamic interaction between fluvastatin and ezetimibe has favourable clinical implications. Atherosclerosis 2001, 2 (Suppl.), 89 (abstract).
29. Kosoglou, T., Meyer, I., Musiol, B. és mtsai: Pharmacokinetic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Atherosclerosis 2000, 151, 135 (abstract).
30. Kosoglou, T., Seiberling, M., Statkevich, P. és mtsai: Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin. J. Am. Coll. Cardiol. 2001, 37 (Suppl. A), 229A (abstract), 1075-1168.
31. Lipka, L. J., LeBeaut, A. P., Veltri, E. P. és mtsai: Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by SCH58235: pooled analysis of two phase II studies. J. Am. Coll. Cardiol., 2000, 35 (Suppl. A), 257A (abstract).
32. Mamo, J. C., Proctor, S. D., Smith, D.: Retention of chylomicron remnant by arterial tissue; importance of an efficient clearance mechanism from plasma Atherosclerosis 1998, 141 (Suppl. 1), S63-S69.
33. Mamo, J. C. L., Smith, D., Yu, K. C. W. és mtsai: Accumulation of chylomicron remnants in homozygous subjects with familial hypercholesterolemia. Eur. J. Clin. Invest., 1998, 28, 379-384.
34. Miettinen, T. A., Gylling, H.: Regulation of cholesterol metabolism by dietary plant sterols. Curr. Opin. Lipidology, 1999, 10, 9-14.
35. Mistry, P., Miller, N. E., Laker, M. és mtsai: Individual variation in the effects of dietary cholesterol on plasma lipoproteins and cellular cholesterol homeostasis in man. Studies of low density lipoprotein receptor activity and HMG-CoA reductase activity in blood mononuclear cells. J. Clin. Invest., 1981, 67, 493-502.
36. National Cholesterol Education Program: Detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). National Institutes of Health, NIH Publication No. 93-3095. Circulation, 1993, 89, 1329-1445.
37. Pearson, T. A., Laurora, I., Chu, H. és mtsai: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Int. Med., 2000, 160, 459-467.
38. Philips, C., Murugasu, G., Owens, D. és mtsai: Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes. Atherosclerosis, 2000, 148, 283-291.
39. Proctor, S. D., Pabla, C. K., Mamo, J. C. L.: Arterial intimal retention of pro-atherogenic lipoproteins in insulin deficient rabbits and rats. Atherosclerosis, 2000, 149, 315-322.
40. Rubinstein, A., Weintraub, M.: Escape phenomenon of low-density lipoprotein cholesterol during lovastatin treatment. Am. J. Cardiol., 1995, 76, 184-186.
41. Russell, D. W.: Cholesterol biosynthesis and metabolism. Cardiovasc. Drugs. Ther., 1992, 6, 103-110.
42. Statknich, P., Reyderman, L., Kosoglou, T. és mtsai: Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide. Clin. Pharmacol. Ther., 2001, 69, P67 (abstract).
43. vanHeek, M., Austin, T. M., Farley, C. és mtsai: Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese, hyperinsulinemic hamsters. Diabetes, 2001, 50, 1330-1335.
44. vanHeek, M., Compton, D. S., Davis, H. R.: The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur. J. Pharmacol., 2001, 415, 79-84.
45. vanHeek, M., Farley, C., Compton, D. és mtsai: Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br. J. Pharmacol., 2000, 129, 1748-1754.
46. vanHeek, M., Farley, C., Compton, D. és mtsai: The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically. Atherosclerosis, 2000, 151, 155 (abstract).
47. vanHeek, M., France, C. F., Compton, D. S. és mtsai: In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J. Pharmacol. Exp. Ther., 1997, 283, 157-163.
48. Vuoristo, M., Miettinen, T. A.: Absorption, metabolism, and serum concentration of cholesterol in vegetarians: effects of cholesterol feeding. Am. J. Clin. Nutr., 1994, 59, 1325-1331.
49. th ed. McGraw-Hill, New York. 1996, 36, 875-897. old.
50. Zhu, Y., Statkevich, P., Kosoglou, T. és mtsai: The effect of gender on the pharmacokinetics of SCH58235, a cholesterol absorption inhibitor. AAPS Pharm. Sci., 1999, 1, S24 (abstract).